Aggressive Non-Hodgkin Lymphoma — Trials

Aggressive Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

648 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 182
Recruiting: 92
Ph III recruiting: 4
Growth YoY: +6.7%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (109)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07476027	Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL	not yet recruiting	Early Phase 1	10	Institute of Hematology & Blood Diseases Hospital, ChinaOTHER	0	Mar 17, 2026	clinicaltrials
NCT07168291	Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma	not yet recruiting	Early Phase 1	3	First Affiliated Hospital Xi'an Jiaotong UniversityOTHER	1	Sep 17, 2025